BIA-ALCL is a rare lymphoma of the immune system that develops in the capsule or fluid surrounding a breast implant, most commonly in textured implants. Symptoms include persistent swelling, a new lump in the breast or armpit, or a fluid collection that occurs usually a year or more after surgery. If these signs appear, prompt investigation is critical - typically including ultrasound or MRI imaging, fluid aspiration for cytology, and surgical removal of both the implant and capsule for tissue sampling and laboratory confirmation.
 

Capsular Contracture occurs when the natural scar tissue around the implant becomes abnormally thick or tight. Early signs include firmness, asymmetry, or discomfort. Treatment may involve capsulectomy, implant exchange, or implant removal depending on severity and patient goals.
 

Ultimately, surgeon technique matters - sterile handling, pocket selection, and incision choice all influence risk. Each patient’s surgical plan is designed to minimise complications while maintaining long-term comfort and symmetry.

Recovery & Expectations

In confirmed cases of BIA-ALCL, surgical excision is the cornerstone of treatment. If the disease has spread, chemotherapy or immunotherapy may be required in collaboration with oncologists in a multidisciplinary setting.
 

For capsular contracture, management depends on individual goals. Some patients may choose implant removal with total capsulectomy, others may pursue Simultaneous Implant Exchange with Fat Grafting (SIEF) or implant exchange with mastopexy for aesthetic restoration.
 

Follow-up visits remain essential for all patients. You will be guided on what to monitor, when to return, and how concerns are escalated promptly should they arise.